[Featured Stock] Nature Cell Rises on Concerns Over Wuhan Pneumonia and Securing Novel Virus Patents
[Asia Economy Reporter Minwoo Lee] As the number of 'Wuhan pneumonia (novel coronavirus)' patients increases in China, countries around the world are on high alert. Amid this situation, the stock price of Naturecell, which has secured patents related to the treatment of the novel virus, is on the rise.
According to the Korea Exchange on the 22nd, as of 9:30 AM, Naturecell's stock price is at 6,690 won. This is about a 4% increase compared to the previous day. It has risen 13% in one month from the three-month low of 5,920 won recorded on December 17 last year.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Exclusive] 450 Billion Won Korean Investment at Risk as Canadian PE Moves to Acquire US Ascend for $99.2 Million
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
It is interpreted that this is because Albaio (formerly R&L Bio), an affiliate of Naturecell, has secured patents for four new substances used in the development of novel flu treatments. Previously, Albaio filed international patents for four new substances extracted from alder trees, which have influenza treatment effects.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
